Fifth Third Wealth Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$237K Sell
4,948
-719
-13% -$30.9K 0.01% 839
2026
Q1
$208K Sell
5,667
-383
-6% -$18.1K 0.01% 781
2025
Q4
$308K Buy
6,050
+19
+0.3% +$972 0.01% 572
2025
Q3
$335K Buy
6,031
+603
+11% +$35.3K 0.01% 513
2025
Q2
$375K Buy
5,428
+1,249
+30% +$85K 0.02% 453
2025
Q1
$290K Buy
4,179
+1,064
+34% +$87.9K 0.02% 504
2024
Q4
$268K Sell
3,115
-544
-15% -$58.8K 0.01% 540
2024
Q3
$436K Buy
3,659
+1,873
+105% +$250K 0.03% 347
2024
Q2
$255K Buy
+1,786
New +$237K 0.02% 479

Other funds holding NVO

Fifth Third Wealth Advisors's NVO Position: Q2 2026 in Review

Fifth Third Wealth Advisors reduced its Novo Nordisk (NVO) stake by 13% in Q2 2026, selling an estimated $30.9K and leaving 4,948 shares worth $237K. The position accounts for 0.01% of the portfolio, ranked #839.

Fifth Third Wealth Advisors first reported a position in NVO in Q2 2024 and has held it in 9 quarters since. The position peaked at $436K in Q3 2024. 387 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Fifth Third Wealth Advisors held 4,948 shares of Novo Nordisk worth $237K as of Q2 2026.
  • Fifth Third Wealth Advisors sold 719 Novo Nordisk shares in Q2 2026, an estimated $30.9K.
  • Novo Nordisk made up 0.01% of Fifth Third Wealth Advisors's portfolio in Q2 2026, its #839 holding.
  • Fifth Third Wealth Advisors first reported a position in Novo Nordisk in Q2 2024 and has held it in 9 quarters since.
  • Fifth Third Wealth Advisors's Novo Nordisk position peaked at $436K in Q3 2024.
  • 387 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.